Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.61 |
| ▸ | CCR1 | P32246 | 1/20 | 0.54 |
| ▸ | CCR8 | P51685 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.41 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422003 | 0.96 | CYP2A6 (0.57) | CYP2A6CCR1CCR8CYP11B1CYP11B2 | |
| SCHEMBL3423404 | 0.90 | CYP11B1 (0.49) | CYP2A6CCR1CCR8CYP11B1CYP11B2 | |
| SCHEMBL3421988 | 0.90 | CYP2A6 (0.67) | CYP2A6CCR1CCR8METAP2TGFBR1 | |
| SCHEMBL18174686 | 0.82 | CYP2A6 (0.47) | CYP2A6CCR1CCR8CYP11B1CYP11B2 | |
| SCHEMBL9290063 | 0.82 | CYP2A6 (0.57) | CYP2A6CCR1CCR8CYP11B1CYP11B2 | |
| SCHEMBL23922342 | 0.82 | CYP11B2 (0.43) | CYP2A6CYP11B1CYP11B2KARS1S1PR1 | |
| SCHEMBL28090003 | 0.82 | CYP11B2 (0.43) | CYP2A6CYP11B1CYP11B2METAP2KARS1 | |
| SCHEMBL14168736 | 0.80 | CCR1 (0.62) | CYP2A6CCR1CCR8METAP2TGFBR1 | |
| SCHEMBL26233967 | 0.80 | CCR1 (0.62) | CYP2A6CCR1CCR8METAP2TGFBR1 | |
| SCHEMBL15161053 | 0.79 | CYP2A6 (0.47) | CYP2A6CCR1CCR8CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277586-A1 | ACCELERATING REPAIR OF MUCOSAL INJURY USING GOLD(III) COMPOUNDS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-09-07 | — | — | US | disclosed |
| US-20230265108-A1 | GOLD(III) COMPOUNDS AND CANCER CELL-SELECTIVE MODULATION OF MITOCHONDRIAL RESPIRATION AND METABOLISM | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-08-24 | — | — | US | disclosed |
| WO-2022026757-A1 | ACCELERATING REPAIR OF MUCOSAL INJURY USING GOLD(III) COMPOUNDS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022026753-A1 | GOLD(III) COMPOUNDS AND CANCER CELL-SELECTIVE MODULATION OF MITOCHONDRIAL RESPIRATION AND METABOLISM | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-2935281-B1 | SPIROISOXAZOLINE COMPOUNDS HAVING AN ACTIVITY POTENTIATING THE ACTIVITY OF AN ANTIBIOTIC | UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 (FR) | 2020-09-09 | — | — | EP | disclosed |
| US-10355284-B2 | Composition, method of preparing the composition, electrode including the composition, and fuel cell including the electrode | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-20180182981-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2018-06-28 | — | — | US | disclosed |
| EP-2504871-B1 | ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTING MATERIAL | NOVALED GMBH (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-8475686-B2 | Bridged pyridoquinazoline or phenanthroline compounds and organic semiconducting material comprising that compound | NOVALED AG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-8475686-B2 | Bridged pyridoquinazoline or phenanthroline compounds and organic semiconducting material comprising that compound | NOVALED AG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20120283437-A1 | Organic Electronic Device Comprising an Organic Semiconducting Material | NOVALED AG (DE) | 2012-11-08 | — | — | US | disclosed |
| US-20120283437-A1 | Organic Electronic Device Comprising an Organic Semiconducting Material | NOVALED AG (DE) | 2012-11-08 | — | — | US | disclosed |
| US-20120012794-A1 | Bridged Pyridoquinazoline or Phenanthroline Compounds and Organic Semiconducting Material Comprising That Compound | NOVALED AG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120012794-A1 | Bridged Pyridoquinazoline or Phenanthroline Compounds and Organic Semiconducting Material Comprising That Compound | NOVALED AG (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2011063927-A1 | ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTING MATERIAL | NOVALED AG (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2010063461-A1 | BRIDGED PYRIDOQUINAZOLINE OR PHENANTHROLINE COMPOUNDS AND ORGANIC SEMICONDUTING MATERIAL COMPRISING THAT COMPOUND | NOVALED AG (DE) | 2010-06-10 | — | — | WO | disclosed |
| EP-2194055-A1 | Bridged pyridoquinazoline or phenanthroline compounds and organic semiconducting material comprising that compound | Novaled AG (DE) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283437-A1 | Organic Electronic Device Comprising an Organic Semiconducting Material | OR10J3, OR51E2, ICMT | CYP2A6 507/4885CCR1 2932/4885CCR8 3428/4885 |
| US-20120012794-A1 | Bridged Pyridoquinazoline or Phenanthroline Compounds and Organic Semiconducting Material Comprising That Compound | PNPO, SDHB, PAH | CYP2A6 1739/4885CCR1 3356/4885CCR8 3408/4885 |
| US-20180182981-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | CACNA2D2, RABGGTA, NUDT1 | CYP2A6 3350/4885CCR1 4473/4885CCR8 4434/4885 |
| US-20230277586-A1 | ACCELERATING REPAIR OF MUCOSAL INJURY USING GOLD(III) COMPOUNDS | ARG2, COX5B, GSR | CYP2A6 1811/4885CCR1 2937/4885CCR8 1915/4885 |
| US-20230265108-A1 | GOLD(III) COMPOUNDS AND CANCER CELL-SELECTIVE MODULATION OF MITOCHONDRIAL RESPIRATION AND METABOLISM | CS, UQCRC1, UQCRC2 | CYP2A6 461/4885CCR1 4308/4885CCR8 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.